Chemotherapy regimens with immunotherapy in advanced gastric cancer: A prognostic study using Cox modeling

Table 2 Side effects associated with three groups treatment, n (%)

Variables	Total (n = 298)	FOLFOX (n = 42)	PSOX (n = 150)	SOX + XDL (n = 106)	P value
Nausea and vomiting					0.186
0	62 (20.81)	3 (7.14)	36 (24.00)	23 (21.70)
1	178 (59.73)	29 (69.05)	86 (57.33)	63 (59.43)
2	51 (17.11)	8 (19.05)	26 (17.33)	17 (16.04)
3	7 (2.35)	2 (4.76)	2 (1.33)	3 (2.83)
Liver toxicity					0.442
0	252 (84.56)	34 (80.95)	125 (83.33)	93 (87.74)
1	41 (13.76)	6 (14.29)	23 (15.33)	12 (11.32)
2	5 (1.68)	2 (4.76)	2 (1.33)	1 (0.94)
Alopecia					0.002
0	176 (59.06)	21 (50.00)	78 (52.00)	77 (72.64)
1	105 (35.23)	20 (47.62)	58 (38.67)	27 (25.47)
2	17 (5.70)	1 (2.38)	14 (9.33)	2 (1.89)
Peripheral sensory neuropathy					0.912
0	147 (49.33)	23 (54.76)	75 (50.00)	49 (46.23)
1	121 (40.60)	15 (35.71)	61 (40.67)	45 (42.45)
2	25 (8.39)	4 (9.52)	12 (8.00)	9 (8.49)
3	5 (1.68)	0 (0.00)	2 (1.33)	3 (2.83)
Fewer neutrophils					0.123
0	213 (71.48)	25 (59.52)	114 (76.00)	74 (69.81)
1	55 (18.46)	12 (28.57)	24 (16.00)	19 (17.92)
2	19 (6.38)	3 (7.14)	5 (3.33)	11 (10.38)
3	10 (3.36)	2 (4.76)	6 (4.00)	2 (1.89)
4	1 (0.34)	0 (0.00)	1 (0.67)	0 (0.00)
Fewer white blood cells					0.352
0	192 (64.43)	25 (59.52)	100 (66.67)	67 (63.21)
1	68 (22.82)	11 (26.19)	28 (18.67)	29 (27.36)
2	27 (9.06)	5 (11.90)	13 (8.67)	9 (8.49)
3	7 (2.35)	0 (0.00)	6 (4.00)	1 (0.94)
4	4 (1.34)	1 (2.38)	3 (2.00)	0 (0.00)
Fewer platelets					0.106
0	213 (71.48)	29 (69.05)	111 (74.00)	73 (68.87)
1	57 (19.13)	9 (21.43)	25 (16.67)	23 (21.70)
2	23 (7.72)	1 (2.38)	12 (8.00)	10 (9.43)
3	5 (1.68)	3 (7.14)	2 (1.33)	0 (0.00)
Anemia					0.429
0	150 (50.34)	21 (50.00)	79 (52.67)	50 (47.17)
1	108 (36.24)	13 (30.95)	54 (36.00)	41 (38.68)
2	26 (8.72)	3 (7.14)	12 (8.00)	11 (10.38)
3	14 (4.70)	5 (11.90)	5 (3.33)	4 (3.77)

FOLFOX: Oxaliplatin plus leucovorin and fluorouracil; PSOX: Plus oxaliplatin and S-1; SOX + XDL: S-1 combined with sintilimab and oxaliplatin.